Evaluation of the Efficacy and Treatment-Emergent Adverse Events of Deuruxolitinib for Moderate to Severe Alopecia Areata: A Dose-Ranging Meta-Analysis of 1,372 Randomized Patients

This meta-analysis of 1,372 patients across three randomized controlled trials assessed the efficacy and safety of deuruxolitinib, a JAK1/2 inhibitor, for moderate to severe alopecia areata. The study found significant hair regrowth improvements, with many patients achieving 75% to 90% improvement from baseline, particularly at the 12 mg dose. Common treatment-emergent adverse events included increased creatinine kinase levels, headaches, and acne, but these were generally manageable. The study concludes that deuruxolitinib is a promising treatment for alopecia areata, though further research is needed to confirm long-term safety.